Condition: Ovarian Cancer · Advanced Ovarian Carcinoma · Fallopian Tube Carcinoma · Sponsor: Dana-Farber Cancer Institute
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
This description comes directly from the study's public registry record.
Hannah Park, BS · 857.215.4936 · revitalize@dfci.harvard.edu
Irene Wang, MPH · 617.582.7238 · revitalize@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Cancer Center-Anschutz | Aurora, Colorado, United States | Recruiting |
| University of Colorado Boulder | Boulder, Colorado, United States | Recruiting |
| Massachusetts General Hospital-Cancer Center | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06710548